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Abstract: The Nef protein is an essential factor for lentiviral pathogenesis in humans and other simians. Despite a 
multitude of functions attributed to this protein, the exact role of Nef in disease progression remains unclear. One of its 
most intriguing functions is the ability of Nef to enhance the infectivity of viral particles. In this review we will discuss 
current insights in the mechanism of this well-known, yet poorly understood Nef effect. We will elaborate on effects of 
Nef, on both virion biogenesis and the early stage of the cellular infection, that might be involved in infectivity 
enhancement. In addition, we provide an overview of different HIV-1 Nef domains important for optimal infectivity and 
briefly discuss some possible sources of the frequent discrepancies in the field. Hereby we aim to contribute to a better 
understanding of this highly conserved and therapeutically attractive Nef function. 
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1. INTRODUCTION 
 Despite the globally declining number of new human 
immunodeficiency virus (HIV) infections [1] and the hopeful 
observation that cure from HIV infection does not seem 
impossible [2], the HIV pandemic still remains a very 
challenging opponent in the 21
st
 century. The ultimate 
solution would lie in the development of an effective and 
practically feasible therapy to eradicate HIV from infected 
patients, in combination with a safe vaccine to prevent new 
HIV infections. While waiting for these seemingly utopian 
breakthroughs, disease control mainly relies on the 
suppression of viral replication in HIV patients, by life-long 
treatment with antiretroviral therapy. However, the 
remarkable ability of the HIV virus to repetitively adapt and 
escape from antiretroviral agents, combined with toxic 
effects of these drugs, creates the need for a continuous 
development of new antiretrovirals. Therefore it is essential 
to keep exploring the HIV replication biology in search for 
new possible therapeutic targets. In this regard, the so-called 
“accessory” proteins of the HIV-1 virus (Nef, Vpr, Vpu, Vif) 
have received increasing attention [3, 4]. In contrast to the 
essential structural and enzymatic HIV proteins (Gag, Pol, 
Env), the accessory proteins are dispensable for viral 
replication in a number of in vitro systems. However, they 
are strongly conserved during in vivo infection and often 
appear to be crucial for viral pathogenesis (reviewed in [5]). 
One accessory protein for which there exists irrefutable 
evidence of its in vivo significance, is the 27-35kDa Nef 
protein. In this review we will focus on this extensively 
studied protein. In particular, we will discuss current insights 
in the well-known yet poorly understood ability of Nef to 
enhance the viral infectivity. 
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2. THE MULTIFACETED NEF PROTEIN 
 As early as 1991, infections of rhesus monkeys with nef-
deleted simian immunodeficiency virus (SIV) revealed a 
dramatic reduction of viral loads and disease progression in 
absence of nef [6]. A couple of years later, the importance of 
HIV-1 Nef in pathogenesis of acquired immune deficiency 
syndrome (AIDS) was also established. Several groups 
reported the presence of deletions in the nef gene in a 
subpopulation of HIV infected patients with low viral loads 
and long-term asymptomatic survival [7-9]. Although some 
patients and monkeys infected with nef-deleted HIV [10, 11] 
or SIV [12] respectively, eventually progress to AIDS, Nef 
does seem to be indispensable for establishment of high viral 
loads and largely accelerates the disease progression. 
Combined with the fact that Nef expression alone can 
independently induce AIDS-like pathologies in mice, 
without the requirement of any other HIV components [13], 
this designated the protein as an attractive candidate for 
therapeutic targeting. This of course evoked a large scientific 
interest in unraveling the specific role that is reserved for 
Nef during the viral life cycle. Twenty years after its initial 
identification as an in vivo pathogenic factor, the number of 
known Nef effects is still increasing year by year. However 
their individual contribution to disease progression as well as 
their precise underlying molecular mechanisms are still 
largely unclear. 
 Like all accessory proteins, Nef contains no enzymatic 
activity nor does it serve a structural function. Instead, Nef 
turned out to be a master in rearranging the signaling and 
trafficking pathways of the infected host cell, in a way that is 
beneficial for the viral replication and spreading. Nef does 
this by physically interacting with specific cellular proteins 
involved in these pathways, through its multiple effector 
domains (reviewed in [14, 15]). Many different biological 
effects result from these interactions and they all seem to co-
operate in a two-way strategy to promote the viral spread: 
firstly, by evading the anti-viral immune responses of the 
host and secondly, by directly enhancing the viral 
replication. The former is mainly based on the well-known  
 
 
Virion Infectivity Enhancement by Lentiviral Nef Proteins Current HIV Research, 2011, Vol. 9, No. 7    475 
capacity of Nef to modulate expression of receptors involved 
in immune response (e.g. MHC-I) on the surface of the 
infected cell. Consequently, the functional interaction 
between the infected cell and a non-infected immune cell is 
disturbed (reviewed in [16]). 
 The effect of Nef on viral replication itself, seems to be 
more complex. Initially, Nef was even considered to 
suppress HIV replication and to promote the establishment 
of latency (hence its name negative regulatory factor) [17]. 
Following some controversial in vitro results [18, 19] and the 
in vivo demonstration of the positive effect of Nef on viral 
load [6], it became clear that Nef does enhance HIV 
replication in vitro, especially in primary cells [20, 21]. In 
contrast to the in vivo situation, viral replication in these in 
vitro environments is not subjected to the influence of a 
complete host immune system. Therefore the enhanced 
replication, observed in vitro, can theoretically be attributed 
to one of the three following mechanisms: (1) It can result 
from an increase in the number of viral particles produced 
and released by infected cells; (2) The transmission of 
viruses from the virus producing cell to the target cell could 
be facilitated; (3) The intrinsic capability of the newly 
produced virions, to infect new target cells (the “viral 
infectivity”) could be enhanced. Over the years it became 
clear that Nef probably operates at all three levels. First, by 
subverting T cell signaling pathways and facilitating T cell 
activation, Nef enhances the activity of the HIV-1 LTR 
promoter, which in turn might promote the virion production 
[22-24]. Furthermore, Nef is thought to increase the release 
of viral particles by downmodulating the CD4 receptor on 
the virus producing cells [25]. Secondly, remodeling of the 
host actin cytoskeleton by Nef might promote the cell-to-cell 
transmission of virions, although this is still controversial 
[26, 27]. Also, in co-cultures of T cells and dendritic cells, 
Nef is thought to enhance the transmission of virus to T cells 
[28]. However, the most widely accepted of these three Nef 
functions, is the capacity of Nef to increase the infectivity of 
viral particles. Nevertheless, the mechanism behind this 
function remains largely obscure and new theories frequently 
arise in literature. In following sections we will discuss 
overall progress in understanding the molecular basis and 
functional mechanism of infectivity enhancement by Nef. 
Furthermore we will point out some possible causes of 
discrepancies in literature. For more in-depth discussion on 
the other possible mechanisms of viral replication 
enhancement by Nef, indicated above, we refer to an 
excellent review on the topic [16]. 
3. INFECTIVITY: WHAT’S IN A NAME? 
 In literature the term “infectivity” generally refers to the 
ability of a pathogen to cause infection of a host. Therefore it 
is often a combination of both its replicative and 
transmission capacities. However, when studying HIV 
infectivity and the contribution of Nef at cellular level, a 
slightly different interpretation is usually applied. This is 
based on the characteristics of the most commonly used 
assay to measure HIV infectivity in vitro: a HeLa-CD4 cell 
line that contains a Tat-responsive lacZ reporter is infected 
with equal amounts of cell-free virus and a single cycle of 
infection is allowed to occur before quantification of the 
amount of infected cells [29, 30]. In this setting, an increase 
in infectivity by Nef represents an increase in the intrinsic 
capability of a viral particle to productively infect a target 
cell, but is independent of effects of Nef on the production of 
viral particles or viral spread over the culture. Since most of 
the research on Nef and infectivity is based on this type of 
assays, we will use this interpretation throughout the review. 
4. LESSONS ON NEF-MEDIATED INFECTIVITY 
ENHANCEMENT FROM MUTATIONAL STUDIES 
 The ability of Nef to enhance infectivity is a highly 
conserved property among different groups of primate 
lentiviruses. In a panel of 30 different Nef alleles from HIV-
1 (groups M, N and O), HIV-2 and a large variety of SIV’s, 
Munch et al. demonstrated that more than 90% of them 
enhanced virion infectivity, although with a sometimes 
variable efficiency [31]. The fact that despite the genetic 
diversity, almost all Nef alleles enhanced infectivity, might 
indicate that different domains of the Nef protein attribute to 
this function. As mentioned before, Nef uses its different 
domains to interact with a large panel of cellular proteins. 
Therefore, identification of the domains involved in a 
particular Nef function, can shed light on the molecular 
mechanism of this function. Since the early nineties, a large 
number of Nef mutational studies have been performed in 
this regard. Some of these studies only focused on particular 
Nef functions and/or domains [32-49], whereas others 
analyzed a broad panel of isogenic mutants to obtain a better 
insight in the relation between different Nef activities and 
their contribution to optimal HIV replication [50-52]. An 
overview of the impact of different Nef mutations on 
infectivity enhancement, as observed in 22 different studies, 
is presented in Table 1. 
 From studies using Nef-mutants deficient in association 
with the cellular membrane, it became clear that membrane-
targeting is important for Nef enhanced infectivity. Both the 
G2A mutation, which abolishes the N-terminal 
myristoylation of Nef [32, 37, 39, 40, 46, 50-53] and 
mutations in a cluster of N-terminal basic residues (R4A4), 
which disrupts membrane targeting of Nef [36], resulted in 
an abundant decrease in infectivity. Furthermore, Giese et al. 
described the importance of two N-terminal lysine residues 
(K4/K7) for infectivity enhancement and showed that these 
residues are critical for incorporation of Nef in the lipid rafts 
[40]. Since these specialized microdomains in the plasma 
membrane are a preferred site for budding of HIV viral 
particles [54], these findings might indicate that the presence 
of Nef at the site of viral assembly is critical for its ability to 
enhance infectivity. Of note, viruses containing a Nef-mutant 
with highly increased lipid raft incorporation, by 
introduction of a palmitoylation site in the N-terminal nef 
region (G3C mutation), do not show a corresponding 
increase in infectivity [55, 56]. This lack of correlation 
between the K4/K7 loss-of-function [40] versus the G3C 
gain-of-function mutation [55, 56] can be interpreted as a 
saturation of the infectivity enhancement effect at 
physiological levels of Nef, since further enrichment of Nef 
in the lipid rafts does not further increase virion infectivity 
[55, 56]. 
 Another Nef motif involved in infectivity enhancement is 
the polyproline stretch PxxP located in the core of the Nef  
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Table 1. Overview of Nef Domain Mutations Reported to Affect Infectivity Enhancement. Different Nef Domains are Separated by 
Alternating Shading 
 
Infectivity Assay 
Mutation HIV-Strain 
P4-R5 
Assay 
TZM-bl 
Assay 
Prim. 
Cells 
Mouse 
Model 
Function of Nef 
Mutated Region 
References 
G2A NL4.3, SF2, R8, HXB, LAI 0 0/+   Myristoylation signal  
[32, 37, 38, 40, 
46, 50-53] 
4-7 HXB Nef +  0    Incorporation lipid rafts [46] 
K4/7A SF2  0   Incorporation lipid rafts [40] 
12-39 SF2  0   
Nef phosphorylation - 
Tat transactivation 
(NAKC)  
[40, 50] 
R17/19/21/22A SF2, NL4.3 0 ++   Membrane targeting [36, 40, 50] 
RER17-19AAA R8 0    Membrane targeting [52] 
M20L NL4.3 ++   ++ MHC1  [48, 53] 
V30A NL4.3 0     [51] 
RD35/36AA NL4.3, R8 +    CD4  [52] 
L37Q NL4.3   ++ 

  CD4  [35] 
C55A R8 +    Protease cleavage site [52] 
CAW55-57LLL HXB Nef +  0    
Protease cleavage site - 
CD4  [38] 
W57A NL4.3, R9, HXB 0/+    
Protease cleavage site - 
CD4  [51, 38, 39] 
L58A R9 +    
Protease cleavage site - 
CD4  [39] 
WL57/58AA NL4.3, R8, R9, HXB 0/+/++  + †  
Protease cleavage site - 
CD4  [38, 39, 44] 
59-61 SF2  0   CD4  [50] 
W61A SF2  +   CD4  [50] 
60-71 HXB Nef +  0    Binding PACS-1 - 
MHC1  [46] 
E62-65A; E66-69A NL4.3, SF2 + + ++ †  
Binding PACS-1 - 
MHC1  [49] 
E62/63Q  R8 +    
Binding PACS-1 - 
MHC1  [52] 
E63A NL4.3 +    
Binding PACS-1 - 
MHC1  [51] 
E64/65Q  R8 +    
Binding PACS-1 - 
MHC1  [52] 
P69A NL4.3 +    
Binding Pak2 and SH3 
domains 
[51] 
P69/72/75/78A NL4.3, R8, HXB 0  + † ++ 
Binding Pak2 and SH3 
domains 
[44, 46, 52, 53] 
P69/72A  NL4.3, R8 +/0    
Binding Pak2 and SH3 
domains 
[52] 
P72/75A, P76/79A LAI, SF2 + +   
Binding Pak2 and SH3 
domains 
[37, 50] 
P73A SF2 0 +   
Binding TCR zeta and 
Pak2 
[45] 
P75/78A  NL4.3, R8 ++/0    
Binding Pak2 and SH3 
domains 
[50, 51, 52] 
P76A SF2 0    
Binding Pak2 and SH3 
domains 
[45] 
RK77/82AA NL4.3 +    
Binding Pak2 and SH3 
domains 
[51] 
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(Table 1) contd….. 
Infectivity Assay 
Mutation HIV-Strain 
P4-R5 
Assay 
TZM-bl 
Assay 
Prim. 
Cells 
Mouse 
Model 
Function of Nef 
Mutated Region 
References 
V78A SF2  +   
Binding Pak2 and SH3 
domains 
[50] 
P78L NL4.3   + 

  
Binding Pak2 and SH3 
domains 
[35] 
P79A SF2 0    
Binding Pak2 and SH3 
domains 
[45] 
T80A NL4.3, R8, HXB 0 +  ++ 
PKC phosphorylation 
site 
[46, 52, 53] 
R81A SF2  +   
Binding Pak2 and SH3 
domains 
[50] 
D86A/H89A R8 0     [52] 
R105/106L; 
R109/110L 
NL4.3, SF2  +  ++ 
Multimerization - 
binding Pak 2  
[50, 53] 
R105/106A NL4.3, R8 +/0/0    
Multimerization - 
binding Pak 2 
[45, 51, 52] 
R105Q isolate sequence* +    
Multimerization - 
binding Pak 2 
[43] 
R106A NL4.3, isolate sequence* ++/0    
Multimerization - 
binding Pak 2 
[43] 
R106Q isolate sequence* 0    
Multimerization - 
binding Pak 2 
[43] 
D108A/D111A R8 0    Binding thioesterase [52] 
D111G NL4.3 0     [51] 
L112A, L116A LAI, SF2 0 +   
Multimerization - 
binding Pak 2 
[37, 50] 
W113A NL4.3 +     [51] 
G119L NL4.3 0     [51] 
F121A LAI 0    
Binding thioesterase - 
dynamin2 
[37] 
D123A LAI 0    
Binding thioesterase - 
dynamin2 - 
multimerization 
[37] 
D123E isolate sequence* 0    
Binding thioesterase - 
dynamin2 - 
multimerization 
[43] 
D123G NL4.3, LAI +/0    
Binding thioesterase - 
dynamin2 - 
multimerization 
[41] 
P136A NL4.3 0     [51] 
W141A NL4.3 +     [51] 
P147A NL4.3 +     [51] 
P147/150A NL4.3 ++   ++  [51, 53] 
E155Q NL4.3, R8, LAI ++    Beta COP binding [37, 51, 52] 
K158E/E160A NL4.3, R8 ++    Binding AP-1/2/3  [51, 52] 
L164/165A; 
L168/169A 
NL4.3, R8, LAI, SF2 0/+ + 0 †  
Binding AP-1/2/3 and 
V1H - CD4  - sorting 
signal  
[42, 44, 47, 50, 
51, 52]  
D174/175A; 
ED178/179AA 
NL4.3, R8, SF2 + + 0 †  
Binding AP-1/2/3 and 
V1H - CD4  - sorting 
signal 
[50, 51, 52] 
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protein [45, 46, 50-52]. This acidic region was demonstrated 
to bind with PACS-1 [57], the SH3-domain of the Src family 
kinases [58] and a complex of cellular proteins including 
Pak-2 [58, 59]. This might indicate that the ability of Nef to 
alter the cellular signaling pathways is important for its 
infectivity enhancing function. However, a direct 
contribution of these interaction partners is not demonstrated 
yet. 
 The dileucine motif in Nef (LL164/165 (nl4-3 allele)) is 
also required for full infectivity of HIV-1 virions. This 
domain is known to mediate the interaction of Nef with the 
clathrin-coated vesicle-associated adaptor complexes (AP-1, 
AP-2, AP-3) and is therefore important for the well-known 
ability of Nef to enhance the internalization and modify the 
intracellular trafficking of membrane proteins [47, 60]. 
Therefore, alteration of membrane protein expression or a 
general disruption of protein trafficking might be required 
for enhancement of virion infectivity. 
 Also oligomerization of the Nef protein was proposed to 
be a determinant of infectivity as demonstrated in studies 
using mutations of two arginine residues at position 105 and 
106 or the aspartic acid residue at position 123 
(RR105/106AA and D123G respectively) [41, 43, 45, 51-
53]. These residues are thought to form salt bridges 
necessary for the stabilization of Nef oligomerization [61, 
62], although this model of oligomerization and the necessity 
of the D123 residue in this regard, was recently challenged 
by Kwak et al. [63]. 
5. MECHANISM OF INFECTIVITY ENHANCEMENT 
BY NEF 
 A well-known fact about Nef-mediated enhancement of 
infectivity, is that the infectivity of nef-deleted virions can be 
rescued completely by expressing Nef in the virus producing 
cell. However, if virions were produced in the absence of 
Nef, their infectivity cannot be rescued by expression of Nef 
in the target cells [30, 64, 65]. This shows that infectivity 
enhancement is not mediated by an action of the newly 
expressed Nef in the infected cell, but requires the presence 
of Nef during production of the viral particles. Therefore, 
Nef must somehow modify the virions during their 
biogenesis and thereby alter their behavior during 
subsequent infection of the target cells. Understanding the 
mechanism of Nef-mediated infectivity enhancement 
consequently consists of two questions: what is the nature of 
the modification imprinted by Nef in the virus producing cell 
and how is the infection process of the viruses affected by 
this modification? 
5.1. Nef-Mediated Modification of Virion Particles in the 
Producer Cell 
5.1.1. Virion Incorporation of Nef 
 The most notable compositional difference between 
virions produced in the absence and presence of Nef, is the 
incorporation of small amounts of Nef itself in the latter [65, 
66] (Fig. 1A). It is therefore tempting to speculate that the 
increased infectivity of Nef-containing virions, results from a 
direct action of these virion-delivered Nef molecules during 
the early steps of infection. The fact that another virion-
incorporated HIV-1 accessory protein, Vpr, is capable of 
enhancing viral infectivity (reviewed [67]) further supports 
such a hypothesis. However, over the years evidence 
accumulated against a role for virion Nef in infectivity 
enhancement. 
 As mentioned earlier, the infectivity of a genetically nef-
deficient virus cannot be rescued by expression of Nef in the 
(Table 1) contd….. 
Infectivity Assay 
Mutation HIV-Strain 
P4-R5 
Assay 
TZM-bl 
Assay 
Prim. 
Cells 
Mouse 
Model 
Function of Nef 
Mutated Region 
References 
D175A NL4.3 +    
Binding AP-1/2/3 and 
V1H - CD4  - sorting 
signal 
[51] 
E177K NL4.3   ++ 

  
Binding cRaf1 kinase - 
CD4   [35] 
ERE177-179AAA NL4.3, R8 +    
Binding cRaf1 kinase - 
CD4   [51, 52] 
E179A NL4.3 +    
Binding cRaf1 kinase - 
CD4   [51] 
W183A NL4.3 0     [51] 
L189A NL4.3 0     [51] 
F191H NA7, Pex**  + ++ ++ ‡  Binding Pak2 [34] 
F191R NA7, Pex** 0 ++ ++ ‡  Binding Pak2 [34] 
H193A NL4.3 +    Binding Pak2 [51] 
++ indicates activity comparable to the wt protein, + intermediate activity and 0 designates loss of function. 
 viral infectivity calculated as percentage of p24+ cells 5 days post-infection; † infectivity calculated as TCID50; ‡ infectivity calculated as % GFP positive cells 3 days post-infection. 
* DNA encoding Nef based on accession numbers AAA87489 and AAD48628. 
** Pex: consensus nef allele based on nef sequences derived from 91 HIV-1 infected individuals at different stages of disease (ref [34]). 
Remark: mutations only studied once and no effect on infectivity found in Hela or TZM-bl assay: 8-15 for HXB2 Nef allele; A56D for NA7 Nef allele; K201A/E204A for R8 Nef 
allele; P82A, R105A, R106K, R4A4 (R17/19/21/22A), E181Q for SF2 Nef allele and K7A, W13A, R17A, M20A, E24A, D36A, E38A, T44A, N51A, V74R, R77A, K82A, D86A, 
F90A, K94A, L100A, N126A, P131A, H166A, H171A, D174G, H199A for NL4.3 Nef allele (ref [43, 45, 46, 48, 50, 51]). 
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target cell [64, 66], rendering an infectivity enhancing 
activity of Nef in the target cell doubtful. Virion-incorpo-
rated Nef is known to be cleaved at its WL57-58 motif by the 
viral protease during virion maturation [65, 66, 68]. It has 
therefore been suggested that trans complementation of Nef 
in the target cell might not provide the correct form of Nef 
[65]. This is however unlikely since HIV Nef mutants and 
SIV Nef proteins that lack the sequence required for protease 
cleavage, are still capable of enhancing viral infectivity [39]. 
 Over the years multiple studies have investigated the 
virion incorporation of Nef mutants with a known defect in 
their ability to increase viral infectivity. These studies 
revealed the existence of both mutants that show efficient 
[38, 50] as well as mutants with inefficient [36, 50, 69] 
virion incorporation. However, correlation analysis does 
neither allow to exclude nor accept a role of virion Nef in 
infectivity enhancement, since incorporated mutants are not 
necessarily functional and non-incorporated mutants might 
also be defective for Nef activities in the producer cell that 
are required to enhance infectivity. Conversely, Fackler et al. 
showed that mutation of the Nef EEEE66-69 acidic stretch 
(SF2 nef allele) by alanine substitution results in loss of 
virion incorporation while maintaining the capacity to 
increase viral infectivity [50]. Since this indicates that 
infectivity enhancement can occur in absence of virion 
incorporated Nef, an active role of virion Nef in this regard 
would become unlikely. However, it has to be noted that the 
absence of this particular Nef mutant in the virion was 
questioned recently [70]. 
 To avoid the use of Nef mutations with possible 
pleiotropic effects, two recent studies tried to manipulate 
virion incorporation of intact Nef by fusing it to proteins 
with known high incorporation levels in HIV-1 virions. Qi et 
al. showed that N-terminal fusion of Nef to the Gag 
interacting host protein Cyclophylin A (CypA), preserved its 
ability to enhance HIV-1 infectivity and resulted in high 
levels of the fusion protein in viral particles. Upon 
pharmacologic or genetic inhibition of the CypA-Gag 
interaction, virion incorporation was disrupted and this 
corresponded with a complete loss of infectivity 
enhancement. Although this study demonstrates a strong 
correlation between virion incorporation of Nef and 
infectivity enhancement, the authors cannot exclude that Nef 
acts prior to virion maturation and budding in the virus 
producing cell [70]. In this regard it is worth noting that N-
terminal fusion will disrupt the myristoylation of Nef. 
Therefore the CypA-Gag interaction in this study might not 
only be required for virion incorporation, but also for 
association of Nef with the site of virion assembly. Another 
system to modulate virion incorporation of unmutated Nef 
proteins was described by Laguette et al. and involves C-
terminal fusion of Nef with the virion incorporated HIV-1 
Vpr protein. By introducing a viral protease cleavage site 
between Nef and Vpr, maturated virions contain high levels 
of the full-length Nef and Nef fragments that are found in 
wild-type HIV-1 virions. Nevertheless, these virions were 
only as infectious as virions produced in the absence of Nef. 
This indicates that an inhibitory effect of the Vpr sequence 
fused to Nef prevents its infectivity enhancing functions in 
the virus producing cell and that the presence of Nef in viral 
particles alone is therefore not sufficient to increase HIV 
infectivity [71]. 
5.1.2. Virion Incorporation of Other Viral Proteins 
 Analogous to the concept of virion Nef levels discussed 
above, Nef might increase the virion infectivity by 
modulating the incorporation of other viral proteins in the 
budding virions. Over the years multiple studies failed to 
detect any differences in the composition of virions produced 
in the presence or absence of Nef, with regard to the amounts 
of genomic RNA, gag-derived structural proteins (CA, MA 
and NC), viral enzymes (RT and IN) and Vpr [30, 50, 56, 65, 
72, 73]. 
 On the other hand, levels of virion envelope 
glycoproteins were shown to be modestly or even highly 
reduced in nef-deleted compared to wild-type to HIV-1 
virions, if these virions were produced in CD4+ expressing 
cells [74-77]. It is known that high cell surface levels of CD4 
can largely decrease the infectivity of viral particles by 
sequestering the viral envelope proteins and preventing their 
incorporation in the nascent virions [75, 77]. Therefore, the 
well-described ability of Nef to downmodulate the CD4 
receptor from the cell surface, is thought to alleviate this 
CD4-mediated blockage of Env incorporation in the virus 
producing cell [74-77]. This phenomenon is known in 
literature as the CD4 dependent mechanism of Nef-mediated 
infectivity (Fig. 1B). Nevertheless, Nef can still increase 
virion infectivity if CD4 is not expressed in the virus 
producing cell [30, 32, 75]. Furthermore, the effect of Nef on 
CD4 and infectivity seems to be genetically separable, since 
certain Nef mutations were demonstrated to affect only one 
of the two functions [46, 52]. Therefore, Nef definitely 
employs CD4-independent mechanisms to enhance virion 
infectivity. In this regard, two more recent reports suggest 
that Nef can even increase the virion Env incorporation in a 
CD4-independent way [35, 78], possibly by reducing the 
retention of Env precursor proteins at the cis-Golgi [78]. 
Another mechanism proposed by Pizzato et al. is Nef-
mediated downregulation of an unknown surface factor that 
sequesters Env [37] (Fig. 1B) However, it has to be noted 
that a Nef-dependent increase of viral envelope levels is not 
observed by all groups, even if virions are derived from CD4 
expressing cells [30, 56, 65, 73]. Although the underlying 
causes of these discrepancies are not clear, producer cell-
type dependent differences might be involved, such as the 
surface levels of CD4 [74, 77]. When considering viruses 
produced by the physiologically more relevant primary 
CD4+ T cells, the extent of this Nef function still remains 
controversial, with studies reporting 600% to only 15% 
decrease of virion Env levels upon viral production in 
absence of Nef [35, 76]. Another confounding factor might 
therefore be the actual contribution of Nef to CD4 
downmodulation at the moment of virus collection, since 
CD4 downmodulation is known to occur in a Nef-
independent manner during later stages of infection, by 
actions of both Vpu and Env. Consequently, the 
corresponding inhibition of Env sequestration by CD4 would 
also become a Nef-independent phenomenon at this time 
point [35]. 
 Alternatively to influencing the amounts of incorporated 
viral proteins, Nef could operate by regulating the post-
translational modification of these proteins. Swingler et al. 
demonstrated that Nef strongly enhances the serine 
phosphorylation of the HIV-1 matrix (MA) proteins during 
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the virion biogenesis and this modification is likely 
performed by Nef-associated cellular kinases [79] (Fig. 1C). 
Furthermore, serine phosphorylation of MA seems to be 
especially important for optimal virion infectivity [80, 81]. 
However, Dorfman et al. demonstrated that Nef is still fully 
capable of enhancing viral infectivity when viruses lack the 
MA protein [82]. Therefore, the actual purpose of this Nef 
effect and its relevance for infectivity enhancement remains 
to be determined. 
5.1.3. Virion Incorporation of Cellular Proteins 
 In addition to viral proteins, virions contain a significant 
amount of host cellular proteins [83-85]. As mentioned 
before, HIV particles egress from the cell through 
specialized microdomains, called lipid-rafts, and thereby 
incorporate the cellular lipid raft-associated proteins (as 
reviewed in [83]). Furthermore, cellular proteins could be 
incorporated into the virion due to their presence at the site 
of viral assembly, for instance by an interaction with a viral 
protein (Fig. 1D). Interestingly, HIV-1 infectivity is known 
to be enhanced by incorporated human leukocyte antigens 
(HLAs) [86, 87], costimulatory molecules (CD80 and CD86) 
[88], and intracellular adhesion molecule-1 (ICAM-1) [89, 
90] probably because they facilitate the association of viral 
particles with the target cells. As mentioned by others [71], it 
is therefore tempting to assume that Nef enhances the virion 
infectivity by modifying the incorporation of cellular 
proteins. To our knowledge, there is currently no published 
data available on the cellular protein content of wild-type 
versus nef-deleted viral particles and therefore, evidence 
supporting this hypothesis is still lacking. However, different 
findings are in line with a mechanism for nef-mediated 
infectivity enhancement based on cellular protein 
incorporation. 
 As mentioned before, there’s a genetic correlation between 
the enhancement of viral infectivity by Nef and its ability to 
alter the intracellular trafficking and sorting of cellular 
membrane proteins [42, 47, 91-94]. Furthermore, Pizzato et al. 
demonstrated that both dynamin2 (Dyn2) and clathrin are 
absolutely required in the producer cell for Nef-mediated 
infectivity enhancement in a CD4-independent way [37]. Since 
both of these proteins are involved in clathrin-mediated 
endocytosis of membrane proteins, this strengthens the theory 
that Nef enhances virion infectivity by altering the membrane 
expression of cellular proteins in the producer cell. It is possible 
that Nef uses this mechanism to alter the protein composition of 
virions budding from these membranes (Fig. 1D). Finally, as 
mentioned above, infectivity of HIV particles is enhanced by 
incorporation of ICAM-1 due to the binding with LFA-1 on the 
target cells [89, 90]. Recently, it was demonstrated that ICAM-1 
expression is up-regulated by Nef in a vascular endothelial cell 
line [95], opening perspectives for a possible cellular target 
protein of Nef involved in infectivity. Therefore, studies 
analyzing the incorporation and exclusion of host proteins in 
virions produced from HIV-infected primary cells with or 
without Nef might reveal new insights in the mechanism of Nef 
enhanced infectivity. 
5.1.4. Lipid Composition of Viral Particles 
 As mentioned before, lipid rafts are a preferential site for 
budding of HIV viral particles and the Nef motifs that target 
Nef into these microdomains seem to be important for its 
infectivity enhancing function [40]. Furthermore, it was 
shown that disruption of these lipid rafts in the producer cell 
decrease the infectivity of Nef-containing viruses, while it 
has no effect on nef-deleted viruses [96]. These findings 
indicate that infectivity enhancement by Nef occurs at the 
site of virion budding. Lipid rafts are, next to their 
incorporation of particular cellular proteins, characterized by 
a specific lipid composition, which resembles the HIV viral 
particle lipid composition [97, 98]. Given the importance of 
host membrane and virion-associated lipids for maintenance 
of retroviral infectivity (reviewed in [54]), several groups 
investigated if Nef might alter the incorporation of certain 
lipid species into the cellular and viral membranes to 
optimize the viral infectivity. 
 In this regard Zheng et al. demonstrated increased levels 
of newly synthesized cholesterol in both cellular lipid rafts 
and virion particles when Nef was present in the producer 
cell [69]. This effect was attributed to two distinct 
mechanisms. First, Nef was shown to stimulate the cellular 
biosynthesis of cholesterol, by augmenting the expression of 
the cholesterol biosynthesis enzyme CYP51. Secondly, they 
identified a cholesterol binding motif in the C-terminal 
region of Nef, which was required for both the increased 
cholesterol incorporation and Nef-mediated infectivity 
enhancement of the viral particles. Therefore, Nef was 
proposed not only to increase synthesis, but also the 
transport of cholesterol to the lipid rafts, resulting in viral 
particles with an increased cholesterol content and a higher 
infectivity [69] (Fig. 1E). Microarray analysis of HIV-1 
infected CD4+ T cell lines by van ‘t Wout et al., 
subsequently revealed an increased expression of multiple 
additional genes involved in cholesterol biosynthesis and 
uptake, during infection. Interestingly, these changes were 
only observed with viruses carrying a functional Nef gene 
[99]. However, we could not confirm the increased 
expression of CYP51 or any of the cholesterol pathway 
genes reported by van ‘t Wout et al., in a microarray study of 
Nef-expressing primary CD4+ T cells (unpublished data). 
An additional mechanism applied by Nef to increase virion 
cholesterol content might be the reduction of cholesterol 
export from infected cells (Fig. 1E). Mujawar et al. 
demonstrated that Nef impairs the efflux of cholesterol from 
monocyte-derived macrophages (MDM’s) by targeting the 
cholesterol transporter ABCA1 and this is associated with 
intracellular lipid accumulation [100]. A similar pheno-
menon was recently demonstrated by the same group in 
primary CD4+ T cells (PBL’s) [101]. Furthermore, when 
ABCA1 cholesterol efflux was artificially stimulated during 
viral production, virions obtained from both MDM’s and 
PBL’s had a lower cholesterol content and an equally 
decreased infectivity. This indeed suggests a necessity for 
limiting cholesterol efflux during viral production in order to 
ensure adequate viral infectivity [100, 101], However, a 
direct correlation between this Nef function and its capacity 
to increase virion infectivity has not been demonstrated yet. 
 Although Nef seems to affect cellular cholesterol 
metabolism in multiple ways, the actual increase of virion 
cholesterol levels by Nef is not universally accepted. A 
lipidome analysis of HIV-1 virions produced in the presence 
or absence of Nef, could not confirm the effect of Nef on  
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Fig. (1). Nef-mediated modifications of the virions during virion biogenesis (at the site of viral assembly). Proposed modifications of nascent 
virions as a consequence of Nef expression in the virus producing cells are represented. (A) Expression of Nef during viral production results 
in incorporation of small amounts of Nef into the budding virion. (B) Nef enhances the incorporation of Env glycoproteins into the budding 
virion, by (left) a CD4-dependent mechanism: Nef downregulates CD4 and prevents sequestration of Env by CD4; by (right) CD4-
independent mechanisms: Nef downregulates a yet unknown Env sequestering factor, other than CD4, in a Dyn-2 dependent way, or Nef 
enhances membrane trafficking of Env by reducing the retention of Env precursors. (C) Nef enhances phophorylation of matrix (MA) 
proteins, mediated by Nef-associated kinases. (D) Nef regulates the incorporation of yet unknown cellular factors into the budding virion, by 
(left) binding to cellular factors, resulting in their co-incorporation with Nef in the virion; by (right) regulating surface expression of cellular 
factors at the site of viral assembly, by affecting their trafficking to the surface membrane or by downregulating them from the cell surface in 
a Dyn2-dependent way. (E) Nef enhances the incorporation of cholesterol into the budding virion in different ways: (1) alteration of cellular 
signaling pathways by Nef results in increased expression of the cholesterol biosynthesis genes and thereby increased synthesis of cellular 
cholesterol; (2) Nef binds to newly produced cholesterol and promotes its transport to the sites of viral assembly; (3) Nef impairs the efflux 
of cellular cholesterol by stimulating proteosomal degradation of the cholesterol transporter ABCA1. 
A. B.
C. D.
E.
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cholesterol content, originally observed by Zheng et al, but 
did observe other Nef-mediated alterations in virion lipid 
composition, such as enrichment of sphingomyelin [56]. 
With regard to cholesterol analysis, this study differed from 
the one of Zheng et al. by performing quantification of the 
total levels of virion cholesterol [56] as opposed to newly 
synthesized cholesterol only [69]. It might be possible that a 
modest increase in newly synthesized cholesterol 
incorporation is not reflected in the total cholesterol levels. 
However, analysis of virions produced from non T-cell lines, 
performed by another group, did show a small increase in 
total cholesterol levels by Nef, although this was not 
statistically significant and did not fully correspond with the 
level of infectivity enhancement [101]. The different 
outcomes in these three studies might therefore also be 
attributed to producer cell dependent differences, such as 
their expression levels of ABCA1 [69, 101]. 
 It is quite clear that host membrane and virion-associated 
cholesterol are indispensable for optimal viral infectivity and 
this seems particularly the case for viruses produced in the 
presence of Nef [69, 101, 102]. This supports the idea that 
Nef-mediated enhancement of the viral infectivity occurs 
through a lipid raft-dependent mechanism in the virus 
producing cells. However, it is still controversial if an 
alteration of the virion lipid composition by Nef takes part in 
this process. Such a modification is anyhow unlikely to fully 
account for the effect of Nef on viral particle infectivity, 
since it is possible to demonstrate a loss of Nef-mediated 
infectivity enhancement, without observing changes in the 
viral lipid composition [37, 56]. 
5.2. Impact of Virion Modification on Infection Events in 
the Target Cell 
 The next question in the Nef infectivity enigma, concerns 
the actual consequence of virion modification by Nef in the 
producer cell, during subsequent infection of the target cell. 
In other words, how do virions, produced in the presence of 
Nef, manage to achieve a higher success-rate of productive 
infection? As mentioned before, the absence of Nef during 
viral production cannot be complemented by expression of 
Nef in the target cell. Therefore, the answer to this question 
most likely involves an increased efficiency of a certain step 
during infection, preceding the transcription of viral genes. 
5.2.1. Impact of CD4-Dependent Virion Modifications on 
Infection Events 
 HIV infection is initiated by binding of the viral envelope 
glycoproteins to the CD4 receptor and CXCR4/CCR5 co-
receptor on the target cell. As mentioned before, Nef is 
thought to enhance the levels of envelope proteins 
incorporated in the virion, especially if they are produced in 
CD4 expressing cells. Therefore, the CD4-dependent 
mechanism of Nef-mediated infectivity enhancement 
probably relies on increasing the number of functional 
envelope-CD4 receptor interactions and thereby the 
likelihood of productive infection (Fig. 2A). Artificial 
modulation of the virion envelope levels has indeed shown 
that the number of productively infected cells in the culture 
increases, when gradually increasing the amount of 
incorporated Env proteins in the virion [103]. Alternatively, 
target cells expressing higher levels of CD4 are more prone 
to productive infection, compared to cells with a lower 
surface density of the HIV receptor [74, 77, 103]. In this 
regard it has been demonstrated that the differences in 
infectivity between Nef-deleted and wild-type virions are 
more pronounced upon infection of cells that express lower 
amounts of CD4. Therefore, the lower amounts of Env 
proteins in the Nef-deleted virions might indeed hamper a 
successful interaction with the CD4 receptor and this 
phenomenon can be overcome by high levels of CD4 on the 
target cell [74, 77]. 
 Of note, two early studies failed to detect a difference in 
the cell surface binding capacities of nef-deleted and wild-
type virions [73, 104]. However, one of these studies 
observed equal amounts of Env proteins incorporated in both 
types of viruses [73]. This again demonstrates that the effect 
of Nef on Env incorporation and therefore interaction with 
the target cell CD4-receptor, is probably dependent on the 
producer-cell and the time point of analysis. 
5.2.2. Impact of CD4-Independent Virion Modifications on 
Infection Events 
 Nef also enhances the infectivity of viruses produced in 
cells that do not express CD4. Just like the virion 
modification responsible for this effect, the step of the 
infection process that is affected by this modification, 
remains elusive. However, over the years some enlightening 
observations have been made. 
 First, the increase in infectivity is already detectable at 
the stage of reverse transcription: infection with a nef-deleted 
virus results in a significantly lower accumulation of both 
early and late reverse transcription products in the cells. 
However, purified nef-deleted and wild-type viruses show an 
equal capability to complete the reverse transcription of their 
genome in a cell-free environment. Therefore the reverse 
transcriptase activity itself is not hampered when virions are 
produced in the absence of Nef [64, 73, 104]. Secondly, 
three different groups demonstrated that the fusion process 
between the viral and cellular membrane was equally 
efficient for nef-deleted en wild-type viruses [105-107]. By 
contrast, larger amounts of viral capsid proteins were 
detected in the cytoplasm, very soon after infection with 
viruses produced in the presence of Nef [108]. The latter 
observation can be interpreted as either an increased 
cytoplasmic delivery of the virion core or an increased 
efficiency of the virion uncoating process [107, 108]. Based 
on these observations, the infectivity advantage of virions 
produced in the presence of Nef, seems to result from an 
increased efficiency of a post-fusion event that occurs before 
completion of reverse transcription. 
 More insight in the nature of this event, can be obtained 
from particular experimental conditions that were able to 
restore the infectivity defect of nef-deleted viruses. These 
have led to different theories regarding the specific stage of 
HIV-1 infection that is favored by Nef-induced virion 
modifications (Fig. 2B) 
5.2.2.1. Facilitation of Virion Core Movement Through the 
Cortical Actin Barrier 
 Soon after the discovery of the effect of Nef on 
infectivity, it was shown that pseudotyping HIV with the 
vesicular  stomatitis  virus   envelope  glycoprotein  (VSV-G)  
Virion Infectivity Enhancement by Lentiviral Nef Proteins Current HIV Research, 2011, Vol. 9, No. 7    483 
overcomes the requirement of Nef in the virus producing cell 
[109, 110]. Conversely, viruses pseudotyped with 
amphotropic murine leukemia virus (MuLV) envelope 
remain dependent on Nef for optimal infectivity [30, 64]. 
While the latter modification preserves normal fusion of the 
viral membrane at the cell surface, the VSV-G envelope 
targets virions for cellular entry via the endocytotic pathway 
and promotes fusion upon endosomal acidification. This 
indicates that the Nef-dependent stage of viral infection can 
be bypassed by a deviation from the normal route of viral 
entry [109-112]. A first hypothesis about the identity of this 
early post-fusion infection stage, was provided by Campbell 
et al. They demonstrated that disruption of the cortical actin 
cytoskeleton in target cells could also replace the need for 
Nef. Since this dense layer of actin just beneath the plasma 
membrane is known to obstruct the infection of several 
pathogens, Nef-induced virion modifications might facilitate 
the movement of the virion core through this cortical actin 
barrier. This stage of infection would however be bypassed 
when virions are targeted for entry through the endosomal 
pathway, which explains the redundancy of Nef for viruses 
pseudotyped with a pH-dependent envelope, such as VSV-G 
[105]. In support of this hypothesis, it was recently 
demonstrated that the cortical actin network indeed poses a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Mechanisms of enhanced infection of the target cell by Nef-modified virions. Proposed steps of the viral infection process that are 
facilitated due to Nef-mediated modifications of the virion. (A) CD4-dependent virion modifications: higher levels of Env glycoproteins in 
the virions results in an increase of functional Env-CD4 receptor interactions and thereby increase of the likelihood of productive infection. 
(B) CD4-independent virion modifications: a yet controversial modification imprinted by Nef during virion production (1) facilitates the 
dilatation of the fusion pore and consequently the cytoplasmatic delivery of the virion core; (2) facilitates movement of the virion core 
through the cortical actin barrier; (3) facilitates activation of the reverse transcription complex; (4) protects the virion core against 
proteosomal degradation. 
A.
B.
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major postentry barrier to HIV-1 infection of resting CD4+ T 
cells [113]. 
 Accumulating evidence however suggest that HIV-1 
might also infect cells by fusing with the endosomal membranes, 
following endocytotic uptake [114, 115]. Although the 
contribution of this pathway to HIV entry of T cells is still 
controversial [116, 117], it appears to be a very prominent 
entry route in HeLa-CD4 cells [115], which are the most 
commonly used cell lines for HIV infectivity assays. 
Furthermore, Pizzato et al. recently reported an ability of 
Nef to enhance infectivity when entry occurs through an 
endosomal pH-dependent route [112]. Therefore, it is likely 
that nef-deleted viruses encounter other obstacles during the 
infection process, in addition to the crossing of the cortical 
actin layer. 
5.2.2.2. Facilitation of the Reverse Transcription Complex 
(RTC) Activation 
 An alternative virion modification that rescues the 
infectivity phenotype of the nef-deleted virus was 
demonstrated by Khan et al. They showed that the presence 
of Nef in the producer cell is not required when reverse 
transcription is artificially initiated in the virion prior to 
infection [72]. As mentioned before, wild type and nef-
deleted virions show equal reverse transcriptase activity in a 
cell-free environment [64, 72, 73, 104]. Therefore, this 
observation points towards a specific block in the infection 
process of the nef-deleted viruses accompanying the stage of 
reverse transcription activation. Unfortunately, current 
knowledge about the time point and the specific event that 
triggers RT activation are quite limited. Initiation of reverse 
transcription seems to require an interaction of the RTC with 
the actin cytoskeleton [118], indicating that intracellular 
trafficking of this complex might be necessary for activation. 
Therefore it was suggested that a Nef-induced virion 
modification might guide the RTC to a specific cellular 
compartment that provides an optimal environment for RT 
activation, such as an adequate nucleotide concentration. 
Alternatively, this virion modification might be necessary to 
recruit one of the many cellular factors involved in the 
intracellular HIV reverse transcription process (reviewed in 
[119]). 
5.2.2.3. Protection Against Proteasomal Degradation 
 During early stages of viral infection, the cellular 
proteasome is thought to behave as an anti-viral defense 
mechanism by degrading viral cores upon cytoplasmic entry. 
This was suggested by different reports that observed an 
increase in HIV-1 infection when target cells were treated 
with proteasome inhibitors during the first hours of infection 
[120, 121]. Recently, Qi et al. demonstrated that this type of 
treatment preferentially enhanced the infectivity of nef-
deleted viruses and therefore results in a large decrease of 
the normal infectivity advantage of Nef-containing viruses. 
This might indicate that Nef-induced virion modifications 
are necessary to render viral particles less susceptible for 
virion core degradation. A possibility, proposed by Qi et al., 
is a specific inhibition of virion protein ubiquitylation by Nef 
in the producer cell, which would limit recognition of the 
virion core by the proteasome complex in the target cell. 
Alternatively and in analogy with a Nef-dependent guidance 
of the RTC, a Nef-induced modification might allow correct 
trafficking of the virion core into a productive infection 
pathway, thereby bypassing a proteasomal cellular 
compartment that would cause abortive infection [70, 122]. 
5.2.2.4. Facilitation of fusion pore dilatation 
 Fusion between the viral and cellular membrane results 
in formation of an initial small fusion pore, which requires 
subsequent enlargement to permit passage of the virion core 
[123, 124]. The theory that Nef-induced virion modifications 
might assist in the latter process, came from the observation 
that larger amounts of capsid proteins are detectable in the 
cytoplasm after infection with wild-type viruses compared to 
nef-deleted viruses. Therefore, Nef was thought to 
specifically promote the infection steps that regulate 
cytoplasmic virion delivery [108]. Since nef-deleted viruses 
are not hampered in their ability to mediate membrane fusion 
[105-107], a facilitation of the fusion pore dilatation by the 
Nef-induced modifications, would be consistent with this 
[106, 112]. As pointed out by others [112], Nef-mediated 
assistance at this particular infection stage is not that 
unlikely, since pore dilatation is known to be a very energy-
demanding process and therefore often a limiting step in 
productive viral infection [125]. However, the higher levels 
of cytoplasmatic viral capsid proteins during wild-type virus 
infection, observed by Schaeffer et al. [108], can be 
interpreted in different ways. The particular technique used 
in this study to isolate cytosolic cell fractions, might 
eliminate nef-deleted virion cores that were stuck in the 
cortical actin barrier [105, 106] or might preferentially detect 
the free viral capsid proteins that are released during virion 
uncoating [107]. 
 Despite many theories about the Nef-dependent stage in 
early HIV infection, a solid model explaining all of the 
above observations is still lacking. A Nef-induced virion 
modification seems to facilitate an early post-fusion event 
and different groups suggested a role in intracellular 
trafficking of early viral complexes. Identification of the 
nature of this event is however hampered by the limited 
knowledge regarding the intracellular localization and order 
of the early HIV infection processes. Furthermore, HIV 
infection pathways seem to be cell-type dependent and 
HeLa-CD4 cells might not always prove a relevant model to 
study these particular events [116, 117]. It will probably 
require identification of the responsible virion modification, 
to fully characterize the Nef-dependent infection step. 
6. IMPORTANCE OF NEF-MEDIATED INFECTI-
VITY ENHANCEMENT FOR HIV REPLICATION 
AND PATHOGENESIS 
 Since the identification of Nef as a virulence factor, an 
important question has been the actual contribution of the 
many Nef activities to viral replication and disease 
progression. A multitude of studies has addressed this by 
evaluating the replicative (and pathogenic) potential of HIV 
and SIV variants with differential activity of specific Nef 
functions, in primary cell cultures or macaques (reviewed in 
[126]). The importance of the infectivity enhancement 
function of Nef for viral replication and pathogenesis 
remains however controversial. Upon discovery of Nef’s 
effect on virion infectivity, this function was thought to be 
responsible for the increase in viral replication kinetics by 
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Nef, observed in cultures of primary CD4+ T cells. It was 
suggested that the enhanced infectivity observed in a single-
round of infection is subsequently potentiated over many 
viral life cycles and would in this way evoke in a major 
increase of the overall growth rates of the viruses [20, 21]. 
However, the actual difference in viral replication kinetics 
between nef-deleted and wild-type viruses, are much less 
spectacular then would be expected if such an amplification 
effect was occurring [26, 64]. Furthermore, different studies 
even failed to find a correlation between the extent of 
infectivity enhancement by different patient-derived or 
specifically mutated Nef alleles and their effect on viral 
replication in primary CD4+ T cells or human lymphoid 
tissue [33, 50, 52], as nef alleles deficient in their ability to 
enhance infectivity, were still fully capable to enhance viral 
replication [52]. In this regard Haller et al. suggested that the 
high efficacy of viral cell-to-cell transmission, which is the 
predominant mode of viral spread in T-cell cultures, might 
override differences in infectivity imprinted by Nef. Since 
viral cell-to-cell transmission is likely also important in vivo, 
this would question the relevance of the infectivity 
enhancement of Nef for HIV pathogenesis [26, 31]. 
However, a study in macaques indicates that this Nef 
function does contribute to efficient viral spread in vivo. 
Infection with an SIV variant that contained a nef allele with 
an intermediate infectivity enhancement function resulted in 
higher viral loads, compared to infection with a variant 
containing a nef allele with complete loss of this function, 
but equal activity in other Nef functions [127, 128]. 
Furthermore, nef alleles derived from macaques with higher 
viral loads were more active in enhancing viral infectivity in 
an in vitro assay, then nef alleles from macaques with low 
viral loads and attenuated disease [127]. Another argument 
for in vivo importance of Nef-mediated infectivity 
enhancement is the high level of conservation of this 
particular Nef function among different groups of primate 
lentiviruses [31]. This indicates the presence of selective 
pressure in vivo to maintain this Nef function. Of note, 
Pizzato et al. recently demonstrated that the glycogag protein 
of murine leukemia viruses is required for optimal infectivity 
of these viruses and can also rescue the infectivity of nef-
deleted HIV. Since both proteins seem genetically unrelated, 
they might have independently acquired an infectivity 
enhancing function during evolution, indicating an important 
role in retroviral biology [129]. 
7. UNDERLYING CAUSES OF DISCREPANCY IN 
INFECTIVITY STUDIES 
 As indicated throughout this review, findings on Nef-
mediated infectivity are often inconsistent across different 
studies, causing confusion about their relevance in the field. 
This is further illustrated by the widely divergent effects of 
Nef domain mutations on infectivity enhancement, as listed 
in Table 1. As mentioned before, differences in the producer 
cell, such as CD4 expression levels, might contribute to 
these discrepancies. However, most of the studies discussed 
here focused on the CD4-independent effects of Nef on 
infectivity and used the same CD4 negative embryonic 
kidney derived cell line, 293T, for viral production. An 
important cause of discrepant results as inferred from Table 
1, is the use of nef alleles derived from different HIV-1 
strains. A striking example in this regard is the Nef G2A 
mutation, which is known to completely abolish the 
infectivity enhancing function of most nef alleles, but causes 
only a moderate decrease in this function for the SF2 nef 
allele [50]. Furthermore, it is known that the dependency on 
Nef for optimal virion infectivity, can be affected by other 
HIV proteins [103]. Therefore, results will likely differ when 
analyzing nef alleles in context of their original genetic 
background or when introducing them in the genetic 
background of another HIV strain. Finally, observed effects 
on infectivity seem highly dependent on the experimental 
assay used to measure infectivity. Two well-known cell lines 
for single-cycle infectivity determination are the P4-CCR5 
and TZM-bl indicator cells. Both of them were originally 
derived from the HeLa cell line and contain an integrated 
copy of HIV-1 long terminal repeat (LTR) linked to a -
galactosidase (P4-CCR5 and TZM-bl) and luciferase gene 
(TZM-bl) [29, 130]. An important difference between the 
two is that TZM-bl cells express much higher levels of CD4 
but lower levels of CXCR4. Furthermore, TZM-bl cells are 
known to be more susceptible to HIV-1 infection, but the 
observed magnitude of Nef-mediated infectivity 
enhancement with this cell-line is often lower [31, 34]. In 
this regard, Schindler et al. reported that the F191R Nef 
mutation affected infectivity enhancement when measured in 
P4-CCR5 cells, but not in the TZM-bl cells [34]. However, it 
might be more relevant to investigate the effect of Nef on 
virion infectivity in primary target cells, instead of these 
indicator non T-cell lines. Different methods applied up till 
now are (1) determination of the % of infected cells 3 to 5 
days after infection, by either the use of reporter viruses or 
intracellular p24 staining [34, 35], or (2) determination of the 
TCID50 [20, 44]. However, it might be difficult to separate 
effects of Nef on infectivity and replication in general, when 
looking more than 36 h post-infection. Single-cycle assays in 
primary cells would overcome this problem, but due to the 
low infection efficiency of cell-free virus, quantification of 
subtle infectivity differences would prove quite difficult at 
such an early time-point. 
CONCLUSION 
 Almost two decades after the discovery of Nef’s ability 
to enhance virus infectivity, the molecular mechanism of this 
function is still elusive. Identification of the virion 
modification imprinted by Nef in the producer cell is 
probably a prerequisite for understanding the behavioral 
difference of wild type and nef-deleted viruses in the target 
cell. Clarification of both parts of the nef-infectivity enigma 
could be hampered by the predominant use of biologically 
less relevant cell types. Viral production in CD4 negative 
producer cell lines is often necessary to study CD4-
independent mechanism of Nef-mediated infectivity 
enhancement, but the mechanism and extent of virion 
modification might prove different in primary producer cells. 
Also, HIV infection pathways in the HeLa-CD4 target cells 
might differ from those in primary target cells. The relevance 
of Nef’s infectivity enhancing function has been questioned 
by lack of correlation with its effect on viral replication. 
However, the high level of conservation among different nef 
alleles indicates the importance of this function for in vivo 
HIV biology and it can therefore be considered as a possible 
therapeutic target. 
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